Reuters logo
3 个月内
BRIEF-ZIOPHARM announces FDA acceptance of IND for CD33-specific CAR-T cell therapy
2017年5月2日 / 上午11点23分 / 3 个月内

BRIEF-ZIOPHARM announces FDA acceptance of IND for CD33-specific CAR-T cell therapy

1 分钟阅读

May 2 (Reuters) - ZIOPHARM Oncology Inc

* Ziopharm oncology announces fda acceptance of ind for cd33-specific car-t cell therapy targeting relapsed/refractory acute myeloid leukemia

* Ziopharm oncology inc - investigator-initiated ind application to fda for a phase 1 trial infusing cd33-specific car(+) t therapy is now active

* Ziopharm oncology inc - first patient to be enrolled in study expected to begin treatment in q3 of 2017. Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below